Tag: subjects

Posted on

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Condition:   Asthma
Interventions:   Drug: Fluticasone furoate (FF) Dry Powder Inhaler;   Drug: Fluticasone propionate (FP) Dry Powder Inhaler;   Drug: Budesonide (BUD) Turbuhaler;   Drug: Placebo (ELLIPTA or DISKUS)
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified December 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Condition:   Hypereosinophilic Syndrome
Interventions:   Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsules
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified July 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inahler;   Drug: Albuterol/Salbutamol
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified April 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets (ALK HDM Tablets) in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days